Take a scalpel to $345 million in California’s stem-cell research waste

A weekly column by Jon CoupalBy Jon Coupal and John Moorlach | Just as good scientists are drawn to conclusions by solid data, the decision whether to spend another $345 million by California’s state-run stem-cell research project should be based on an objective analysis as to whether it would be cost-effective. A rigorous cost-benefit analysis is not only fiscally prudent, it avoids being drawn into the moral dilemmas posed by stem-cell research, especially with respect to cells from human embryos.

State Senator John MoorlachCreated in 2004 with the passage of Proposition 71, the California Institute for Regenerative Medicine was authorized to spend $3 billion in bond proceeds. But as is typical with most bonds, the interest payments would double the cost to $6 billion. CIRM has made $2.4 billion in grants and used $255 million for administration and prepaid interest — leaving $345 million remaining to disburse.

Should CIRM distribute the remaining $345 million (which, with interest, would amount to $690 million in repayment costs)? Should this remaining pool of funds be doled out?

To read the entire column, please click here.

This entry was posted in Howard Jarvis Taxpayers Association, John Moorlach, Jon Coupal. Bookmark the permalink.

Comments are closed.